Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
RESEARCH TOOLSreports
Holding NMRA?
Track your performance easily
NMRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.33 - $21.00
Previous Close$9.86
Volume817.33K
Average Volume (3M)1.04M
Market Cap
$1.59B
Enterprise Value$1.25B
Total Cash (Recent Filing)$341.31M
Total Debt (Recent Filing)$2.75M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 06, 2025EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding161,561,064
10 Day Avg. Volume1,216,817
30 Day Avg. Volume1,039,033
Standard Deviation0.22
R-Squared0.38
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)4.18
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.23
Forecast
1Y Price Target
$24.17Price Target Upside146.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Neumora Therapeutics, Inc. News
PremiumCompany Announcements
Neumora Therapeutics Reports Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Drug Development And Market PotentialNavacaprant's novel KOR mechanism allows it to treat anhedonia, a significant unmet need in major depressive disorder, and it has a potential best-in-class safety and tolerability profile.
Financial StabilityNMRA's cash runway was extended to mid-2026, which is seen as encouraging for the company's financial stability.
Stock Price PotentialA positive readout from the Ph 3 KOASTAL-1 study should drive significant upside in the stock price.
Bears Say
Clinical StudiesThe interim analysis built into the KOASTAL study adds an element of uncertainty for investors, contributing to the negative stock reaction.
Market RisksIt is difficult to continue to recommend adding to NMRA positions given the risk/reward skew at current levels, with roughly equal downside and upside barring best case results.
Regulatory ChallengesNMRA recently experienced its own setback with NMRA-266, its lead candidate, facing an FDA clinical hold.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $8.33 and its highest was $21.00 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 105 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.391 by -$0.059.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -$0.42.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 161,561,070 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.391. Following the earnings report the stock price went down -17.082%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Among the largest hedge funds holding Neumora Therapeutics, Inc.’s share is Baker Bros Advisors LP. It holds Neumora Therapeutics, Inc.’s shares valued at 14M.
---
Neumora Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.17 (146.88% Upside)
$24.17 (146.88% Upside)
Blogger Sentiment
Bearish
NMRA Sentiment 67%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.9%
Last 30 Days ▲ 20.2%
Last 30 Days ▲ 20.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.03%
12-Months-Change
Fundamentals
Return on Equity
-70.48%
Trailing 12-Months
Asset Growth
-35.28%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
---
NMRA Earnings Call
Q3 2024
0:00 / 0:00
---
NMRA Stock 12 Month Forecast
Average Price Target
$24.17
▲(146.88% Upside)
Technical Analysis
Best Analysts Covering NMRA
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+5.79%
reiterated a buy rating 9 days ago
Copying Brian Abrahams's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +5.79% per trade.
---